Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
复制标题
DOI：
10.1084/jem.161.2.378
复制
发表时间：
1985-02-01
影响因子：
15.3
通讯作者：
Seaman, W E
中科院分区：
文献类型：
--
作者：
Wofsy, D;Seaman, W E
自身免疫NZB/NZW小鼠每周注射一次L3 T4单克隆抗体（mAb），L3 T4是一种在不同T细胞亚群上表达的抗原，对II类主要组织相容性抗原有反应。与用盐水或用纯化的非免疫大鼠IgG处理的对照小鼠相比，用抗L3 T4处理耗尽循环靶细胞，减少自身抗体产生，延缓肾病，并延长寿命。这些发现证实了NZB/NZW小鼠的自身免疫性疾病受T细胞调节。与用非免疫大鼠IgG处理的小鼠相反，用大鼠抗L3 T4 mAb处理的小鼠产生很少或没有产生针对大鼠IG的抗体。因此，实现了用抗L3 T4治疗的益处，同时使与宿主对治疗的免疫应答相关的风险最小化。这项研究提出了用抗Leu-3/T4的mAb治疗的可能性，Leu-3/T4是L3 T4的人类同源物，可能有效地治疗人类某些自身免疫性疾病。
Autoimmune NZB/NZW mice were treated with weekly injections of monoclonal antibody (mAb) to L3T4, an antigen expressed on a distinct subpopulation of T cells that respond to class II major histocompatibility antigens. Treatment with anti-L3T4 depleted circulating target cells, reduced autoantibody production, retarded renal disease, and prolonged life relative to control mice treated either with saline or with purified nonimmune rat IgG. These findings establish that autoimmune disease in NZB/NZW mice is regulated by T cells. In contrast to mice treated with nonimmune rat IgG, mice treated with rat anti-L3T4 mAb developed little or no antibody to rat Ig. Thus, the benefits of treatment with anti-L3T4 were achieved while minimizing the risks associated with a host immune response to therapy. This study raises the possibility that treatment with mAb against Leu-3/T4, the human homologue for L3T4 might be effective in the treatment of certain autoimmune diseases in people.